Cigna Group: FTC administrative complaint alleging insulin price inflation by Express Scripts 2025

SECTION 1 of 22: FTC Docket No. 9434: The Administrative Complaint Alleging Insulin Price Inflation

The September 2024 Filing

On September 20, 2024, the Federal Trade Commission (FTC) filed a formal administrative complaint against the three largest Pharmacy Benefit Managers (PBMs) in the United States: Caremark Rx (CVS Health), Express Scripts (The Cigna Group), and OptumRx (UnitedHealth Group). The complaint, which followed a two-year investigation, alleged that these entities engaged in anticompetitive and unfair rebating practices that artificially inflated the list price of insulin. The FTC charged that the PBMs, which shared control approximately 80% of the prescription drug market, created a perverse incentive structure that prioritized high-list-price drugs over lower-cost alternatives to maximize rebate revenue.

The Commission’s vote to file the complaint was 3-0, with two commissioners recused. The action marked a significant escalation in federal scrutiny of the PBM industry, moving from investigative studies to direct litigation. The core accusation centered on the “chase-the-rebate” strategy, where PBMs allegedly threatened to exclude insulin products from their formularies unless manufacturers increased list prices to fund larger rebates. This practice, the FTC argued, directly harmed patients with deductibles and coinsurance who are forced to pay the inflated list price at the point of sale, rather than the negotiated net price.

The “Chase-the-Rebate” method

The complaint detailed the mechanics of the rebate system. PBMs negotiate rebates with drug manufacturers in exchange for placement on health plan formularies. The FTC alleged that Express Scripts and its peers systematically excluded lower-list-price insulins in favor of products with high Wholesale Acquisition Costs (WAC) and high rebates.

According to the complaint, this system created a feedback loop:

“Even when lower list price insulins became available that could have been more affordable for patients, the PBMs widespread excluded them in favor of high list price, highly rebated insulin products.” , Federal Trade Commission, September 2024

The FTC internal documents and market data showing that manufacturers, including Eli Lilly, Novo Nordisk, and Sanofi, raised list prices to meet PBM demands for higher rebates. For example, the list price of Humalog increased by over 1, 200% between 1999 and 2017. While net prices (the cost after rebates) frequently stabilized or decreased in later years, the list price, which determines the out-of-pocket cost for patients, continued to rise or remain artificially high.

Financial Impact and Market Data (2015, 2025)

Data from the Health Care Cost Institute and other sources corroborate the widening gap between list and net prices during the relevant period. Between 2012 and 2021, the average list price for a 30-day supply of insulin rose by 184%, from $271 to $499. yet, the commercial discounts (rebates) demanded by PBMs increased disproportionately.

Table 1. 1: Insulin Price and Rebate Trends (Selected Metrics)

Metric	2012 Value	2019 Value	Trend
Avg. List Price (30-day supply)	$271	$541	+100% Increase
Commercial Discount (Long-Acting)	22. 7%	64. 8%	+42. 1 pts Increase
Commercial Discount (Short-Acting)	37. 9%	66. 1%	+28. 2 pts Increase
Net Price Growth (Annualized)	—	Flat / Negative	from List Price

By 2024, Express Scripts held a 30% share of the PBM market, overtaking CVS Caremark. This market dominance allowed the company to exert significant pressure on manufacturers. The FTC alleged that Express Scripts retained hundreds of millions of dollars in rebate revenue annually, rather than passing those savings fully to plan sponsors or patients. The complaint highlighted that for patients with high-deductible health plans, the “spread” between the list price and the net price represented a direct financial transfer from the patient to the PBM and the insurer.

The February 2026 Settlement

On February 4, 2026, the FTC announced a landmark settlement with The Cigna Group and its subsidiary Express Scripts, resolving the administrative complaint. The agreement requires Express Scripts to fundamentally alter its business model regarding insulin and other drugs.

Under the terms of the settlement:

• Delinking Compensation: Express Scripts must delink its compensation from drug list prices, removing the incentive to favor higher-priced drugs.
• Formulary Reform: The PBM is prohibited from excluding lower-cost insulin products from its standard formularies in favor of high-list-price versions.
• Reshoring Operations: Express Scripts agreed to move its group purchasing organization (GPO), Ascent Health Services, from Switzerland back to the United States to increase regulatory transparency.
• Net Cost Model: The company must offer plan sponsors a standard benefit design where patient out-of-pocket costs are based on the net cost of the drug, not the list price.

The FTC estimates that these changes reduce patient out-of-pocket costs for insulin and related drugs by approximately $7 billion over the decade. The settlement does not include an admission of liability by Express Scripts, which continues to assert that its negotiations save money for clients. yet, the structural changes mandated by the order address the core “chase-the-rebate” allegations central to Docket No. 9434.

Legal and Industry

The administrative complaint and subsequent settlement represent a pivot in antitrust enforcement against vertical integration in healthcare. By targeting the rebate method itself, the FTC challenged the standard operating procedure of the PBM industry. The requirement to reshore Ascent Health Services specifically the use of offshore GPOs to obscure financial flows.

While the settlement resolves the case against Express Scripts, litigation against other major PBMs continues. The data established in this proceeding, specifically the between list and net prices and the correlation with rising rebate rates, serves as a foundational record for ongoing legislative and regulatory efforts to cap insulin prices and mandate PBM transparency.

February 2026 Settlement: Express Scripts Agrees to Delink Rebates from List Prices

On February 4, 2026, the Federal Trade Commission (FTC) finalized a settlement with Cigna Group’s Express Scripts, resolving the administrative complaint filed in September 2024 regarding insulin price inflation. The agreement mandates that the pharmacy benefit manager (PBM) fundamentally restructure its revenue model by delinking manufacturer rebates from drug list prices. This move addresses the core allegation that PBMs incentivize higher sticker prices to extract larger rebates from pharmaceutical companies.

Under the terms of the consent order, Express Scripts must offer a standard contract to plan sponsors that bases patient out-of-pocket costs on net drug prices rather than inflated list prices. The FTC projects this structural shift reduce consumer out-of-pocket spending on insulin and other medications by approximately $7 billion over the decade. The settlement also requires Express Scripts to cap monthly insulin copays at $25 for all members within its standard formulary offerings.

Operational Overhaul and Transparency Requirements

Beyond pricing adjustments, the settlement enforces strict operational changes intended to unclear offshore profit centers. Express Scripts agreed to reshore its group purchasing organization (GPO), Ascent Health Services, from Switzerland to the United States. This repatriation subjects the GPO to direct U. S. regulatory oversight, closing a jurisdiction gap that critics argued allowed PBMs to hide rebate flows from auditors.

The agreement imposes a 10-year monitoring period during which Express Scripts must provide drug-level reporting to the FTC. These disclosures track payments to brokers and verify compliance with the transparency mandates. even with these concessions, the settlement stipulates no monetary penalties for Cigna Group, and the company did not admit to any liability or wrongdoing.

route for Major PBMs

The February 2026 agreement isolates Express Scripts from its primary competitors, CVS Caremark and Optum Rx (UnitedHealth Group), both of which remain defendants in the FTC’s ongoing litigation. While Express Scripts opted to settle following the suspension of proceedings in January 2026, the FTC confirmed that its lawsuit against the remaining “Big Three” PBMs continues. The agency maintains that the industry’s rebate-driven model constitutes an unfair method of competition that harms patients dependent on life-sustaining medications.

Key Terms of the February 2026 FTC-Express Scripts Settlement

Provision	Requirement Details
Rebate Structure	Must delink PBM compensation from drug list prices in standard offerings.
Insulin Pricing	Mandatory $25 monthly out-of-pocket cap for members.
GPO Location	Ascent Health Services must relocate from Switzerland to the U. S.
Financial Penalty	$0 (No admission of liability).
Oversight	10-year federal monitoring period with mandatory drug-level reporting.

The Mechanics of Rebate Arbitrage

At the heart of the Federal Trade Commission’s administrative complaint against The Cigna Group’s Express Scripts lies a financial method known as “rebate arbitrage.” This practice fundamentally inverts the traditional logic of market competition: instead of competing to offer the lowest price, drug manufacturers are incentivized to artificially list prices to generate larger rebate pools for pharmacy benefit managers (PBMs).

The method functions through a contractual structure where PBM revenue is calculated as a percentage of the drug’s Wholesale Acquisition Cost (WAC), or list price. When a drug manufacturer sets a high list price, they can offer a substantial “rebate” back to the PBM in exchange for preferred placement on the insurance formulary. If a manufacturer attempts to lower the list price, the rebate value shrinks, causing the PBM to lose revenue. Consequently, PBMs like Express Scripts have systematically excluded lower-cost drugs, including authorized generics, from their standard formularies because these affordable alternatives do not generate sufficient rebate revenue to satisfy the PBM’s profit model.

The “Chase-the-Rebate” Feedback Loop

The FTC’s investigation, corroborated by a 2021 Senate Finance Committee report, details a “chase-the-rebate” strategy that created a perverse feedback loop. Between 2012 and 2017, the list price of insulin products skyrocketed not due to manufacturing cost increases or clinical innovation, to satisfy PBM demand for higher rebates.

For example, the list price of Eli Lilly’s Humalog rose from approximately $21 in 1999 to over $274 by 2017, a 1, 200% increase. Yet, the net price, the amount the manufacturer actually retains after paying rebates to PBMs, remained relatively flat or even declined during later periods. Manufacturers like Sanofi, Novo Nordisk, and Eli Lilly raised prices in lockstep, knowing that failure to offer the largest rebate would result in their products being dropped from the Express Scripts National Preferred Formulary, cutting them off from millions of patients.

Exclusion of Authorized Generics

The most damning evidence of rebate arbitrage is the treatment of “authorized generics” and biosimilars. These are chemically identical insulins sold at a fraction of the brand-name list price. Under a functional market, a PBM acting in the client’s best interest would prioritize these lower-cost drugs.

yet, the FTC complaint alleges that Express Scripts actively blocked these affordable options. When manufacturers introduced unbranded versions of insulins like Lantus or Humalog at list prices 50% to 65% lower than the brand name, Express Scripts frequently excluded them from coverage. The lower list price meant a smaller rebate spread, rendering the cheaper drug “financially toxic” to the PBM’s business model, even though it would have saved patients and plan sponsors millions of dollars directly.

FTC Allegation Summary: “Express Scripts created a perverse drug rebate system that prioritizes high rebates from drug manufacturers, leading to artificially inflated insulin list prices… even when lower list price insulins became available, the PBMs widespread excluded them in favor of high list price, highly rebated insulin products.”

The Financial Spread: List vs. Net Price

The between the price charged to patients and the price paid by the PBM reveals the of the arbitrage. In 2019, data indicated that PBMs could pay a net price as low as $52 per vial for certain insulins after rebates were collected. yet, patients with high-deductible health plans or coinsurance requirements were frequently forced to pay the full list price, sometimes exceeding $350 per vial, at the pharmacy counter.

This gap represents a transfer of wealth from sick patients to the PBM and the insurance plan. The patient pays the inflated list price, while the PBM collects the rebate on the back end., the rebate collected by the PBM exceeded the actual cost of the drug, meaning the PBM made a profit of over 100% on the transaction, subsidized entirely by the patient’s out-of-pocket overpayment.

Table 3. 1: The Insulin Price Gap (2019 Example Metrics)

Metric	Amount	Description
List Price (WAC)	$350. 00	Price used to calculate patient deductible/coinsurance.
Net Price	$52. 00	Actual cost after rebates (hidden from patient).
Rebate Spread	$298. 00	Difference retained by PBM/Payer or used to offset premiums.
Patient Overpayment	~$298. 00	Amount paid by patient above the true market cost.

widespread Impact on Patient Costs

This rebate-centric model weaponized the insurance deductible. For patients with chronic conditions like diabetes, the “benefit” of insurance was nullified. Instead of the insurance company negotiating a lower price for the member, the PBM negotiated a high price to extract a rebate, leaving the member to pay the inflated cost until their deductible was met.

The September 2024 administrative complaint highlighted that this system forced populations, those who are uninsured or in the deductible phase of their coverage, to subsidize the premiums of the healthy. By retaining a portion of the rebates (frequently undisclosed) and using the rest to lower general premiums, Express Scripts and other PBMs created a structure where the sickest patients paid the highest margins.

The Swiss Loophole: Reshoring Ascent Health Services to United States Jurisdiction

The Schaffhausen Shield

In 2019, The Cigna Group established Ascent Health Services, a group purchasing organization (GPO) domiciled in Schaffhausen, Switzerland. While Cigna marketed Ascent as a method to aggregate purchasing power and lower drug costs, federal investigators and the Federal Trade Commission (FTC) alleged the entity served a different primary function: to act as an offshore unclear in the rebate flow, shielding billions of dollars in pharmaceutical manufacturer payments from U. S. regulatory scrutiny and client audits. By locating the GPO outside the United States, Cigna created a jurisdictional firewall, complicating the ability of plan sponsors and federal regulators to track the precise movement of funds between insulin manufacturers and its pharmacy benefit manager (PBM), Express Scripts.

The operational structure of Ascent allowed it to collect administrative fees and “volume-based” payments from drugmakers that were distinct from the standard rebates passed through to health plans. Between 2019 and 2024, this dual-payment stream became a focal point of the FTC’s investigation. The Commission’s September 2024 administrative complaint specifically targeted this architecture, arguing that the offshore GPO enabled Express Scripts to retain a larger share of manufacturer revenue while technically complying with “100% pass-through” contracts in the United States. Because the fees were collected by a Swiss entity for “procurement services,” they were frequently categorized differently than domestic rebates, allowing the PBM to exclude them from the revenue shared with employers and insurers.

Regulatory Evasion and the OPM Audit

The financial of the Swiss strategy were laid bare by a 2024 audit conducted by the Office of Personnel Management (OPM) Office of the Inspector General. The audit examined the prescription drug benefits provided to federal employees and discovered that Ascent Health Services had retained approximately $16 million in manufacturer payments that should have been passed on to the Compass Rose Health Plan. The Inspector General found that while the domestic contract required transparency, the offshore GPO’s involvement obscured the true net cost of medications, including insulin.

This practice of “rebate arbitrage” relied on the separation of the GPO from the PBM. Manufacturers paid Ascent for formulary access, and Ascent, in turn, paid Express Scripts. The difference between what the manufacturer paid and what the PBM reported to its clients represented a hidden profit margin. During the 2023-2025 period, Senate Finance Committee Chairman Ron Wyden and House Oversight Committee Chairman James Comer launched parallel investigations into this structure. In letters sent to Cigna executives in August 2025, Chairman Comer explicitly accused the company of using Ascent to “evade transparency and oversight in the United States,” noting that the Swiss domicile served no clear clinical or logistical purpose for a company primarily serving U. S. patients.

Piercing the Corporate Veil

The FTC’s legal strategy in 2024 hinged on piercing this corporate veil. The Commission’s complaint alleged that Ascent was not a true independent GPO a wholly-owned subsidiary operating as an extension of Express Scripts. By naming Ascent as a co-defendant, the FTC asserted jurisdiction over the Swiss entity, challenging the legality of its fee structures under Section 5 of the FTC Act. The complaint detailed how Ascent’s negotiations with insulin manufacturers, such as Eli Lilly, Novo Nordisk, and Sanofi, prioritized high list prices to maximize the administrative fees calculated as a percentage of the Wholesale Acquisition Cost (WAC).

Evidence presented during the investigation showed that Ascent’s employees, though nominally based in Switzerland, reported directly to Cigna executives in the United States. The “Swiss Loophole” was thus characterized not as a passive investment as an active instrument of price inflation. The structure incentivized the retention of high-list-price insulins on formularies because a drop in the list price would directly reduce the revenue Ascent collected. This misalignment of incentives forced American diabetics to pay inflated out-of-pocket costs while the GPO accumulated fees in a low-tax jurisdiction.

The 2025 Collapse of the Offshore Model

By late 2025, the viability of the Swiss GPO model had under the weight of mounting legal pressure and the impending FTC trial. The exposure of the OPM audit findings and the aggressive discovery process initiated by the FTC made the offshore defense untenable. Cigna faced the prospect of having its internal communications regarding Ascent’s tax and regulatory advantages made public in federal court.

The culmination of this pressure was the of the Swiss loophole. As part of the resolution to the FTC’s administrative complaint, Cigna agreed to a binding requirement to reshore Ascent Health Services to the United States. This forced repatriation, scheduled to be completed by July 2028, brings the GPO’s operations, assets, and data fully under U. S. jurisdiction. The move ends the era of the offshore PBM rebate aggregator for Cigna, subjecting Ascent to the same transparency regulations, audit rights, and anti-kickback statutes that govern domestic healthcare entities. The reshoring represents a tacit admission that the offshore structure was a liability in the face of modern antitrust enforcement.

Table 4. 1: Ascent Health Services, Key Operational Metrics (2019-2025)

Metric	Details
Domicile	Schaffhausen, Switzerland (2019-2025)
Parent Company	The Cigna Group (via Evernorth/Express Scripts)
Primary Function	Rebate Aggregation & Formulary Negotiation
Key Allegation	Retaining “GPO Fees” to bypass 100% pass-through contracts
OPM Audit Finding (2024)	$16 million in retained rebates from federal employee plans
FTC Status	Named Co-Defendant in Docket No. 9434 (Sept 2024)
Resolution	Mandatory Reshoring to U. S. Jurisdiction (Agreed Feb 2026)

“The Committee is investigating whether Cigna Group’s Evernorth Health Services… uses its foreign headquartered group purchasing organization (GPO), Ascent Health Services, Inc…. to evade transparency and oversight in the United States.”
, James Comer, Chairman, House Committee on Oversight and Accountability (August 28, 2025)

The Rise of the Virtual Manufacturer

In 2021, The Cigna Group quietly incorporated Quallent Pharmaceuticals, a private-label subsidiary originally domiciled in the Cayman Islands. This entity functions as a “virtual manufacturer,” a corporate structure that allows Cigna to market and price drugs without owning the physical production facilities. Instead of manufacturing pharmaceuticals, Quallent purchases drugs from established producers, such as Alvotech, Teva, and Boehringer Ingelheim, and resells them under its own National Drug Codes (NDCs). This arrangement enables Cigna’s pharmacy benefit manager (PBM), Express Scripts, to designate Quallent products as preferred on patient formularies, steering revenue back to the parent company.

The Federal Trade Commission’s September 2024 administrative complaint identified this vertical integration as a primary method for price inflation. By controlling the “manufacturer” node in the supply chain, PBMs can set artificial list prices for their own private-label drugs. These inflated list prices generate larger rebates, which the PBM then retains or shares minimally with plan sponsors. While Quallent’s initial portfolio focused on commodity generics, its scope expanded rapidly between 2024 and 2025 to include high-cost biosimilars and insulin products, directly implicating it in the FTC’s allegations of market manipulation.

Quallent’s Role in the Insulin Market

Although Quallent garnered significant attention for its 2024 launch of private-label adalimumab (a biosimilar to Humira), regulatory filings confirm its entry into the insulin sector. State drug transparency data from Nevada and other jurisdictions lists Quallent Pharmaceuticals as the labeler for Insulin Lispro (a rapid-acting insulin analogous to Humalog) and Insulin Degludec (analogous to Tresiba). By introducing these private-label insulins, Cigna positioned itself to capture the full economic margin of the drug.

The operational mechanics mirror the rebate arbitrage strategies attacked by the FTC. Express Scripts could exclude lower-cost generic insulins from its standard formularies in favor of Quallent’s versions. Even if Quallent’s product carried a high list price, the vertical relationship meant the “rebate” paid by Quallent to Express Scripts was simply an internal transfer of funds within The Cigna Group. This circular flow of capital allowed the conglomerate to maintain high list prices for patients, who frequently pay coinsurance based on that list price, while booking the rebate revenue as profit.

Financial Engineering Over Pharmaceutical Innovation

Quallent represents a shift from pharmaceutical innovation to financial engineering. The subsidiary conducts no research and development. Its primary function is to secure supply agreements and hold the NDCs that Express Scripts prioritizes. In May 2024, Boehringer Ingelheim announced it would manufacture its interchangeable biosimilar Cyltezo for Quallent. Similarly, Alvotech agreed to produce high-concentration adalimumab for Quallent’s private label. These partnerships allowed Quallent to offer “co-pay assistance” programs that ostensibly lowered costs for patients kept the underlying insurance reimbursement rates high.

The table outlines the known manufacturing partnerships and product categories for Quallent Pharmaceuticals as of late 2025.

Table 5. 1: Quallent Pharmaceuticals Verified Product Partnerships (2024-2025)

Product Category	Reference Brand	Manufacturing Partner	Quallent Role	Market Entry
Biosimilar	Humira (Adalimumab)	Boehringer Ingelheim	Private Label Distributor	May 2024
Biosimilar	Humira (Adalimumab)	Alvotech / Teva	Private Label Distributor	June 2024
Insulin	Humalog (Insulin Lispro)	Undisclosed (Contract)	NDC Labeler	2024
Insulin	Tresiba (Insulin Degludec)	Undisclosed (Contract)	NDC Labeler	2025
Specialty Generic	Zytiga (Abiraterone)	Various	Distributor	2023

Impact of the February 2026 Settlement

The February 4, 2026, settlement between the FTC and Express Scripts fundamentally alters Quallent’s business model. The consent order requires Express Scripts to “delink” manufacturer compensation from drug list prices and adopt an “acquisition-cost-plus” reimbursement model for its retail pharmacy networks. This mandate the incentive to Quallent’s list prices. Under the new terms, Express Scripts must reimburse pharmacies based on the actual acquisition cost of the drug plus a fixed professional dispensing fee, rather than a percentage of an artificial list price.

also, the settlement’s requirement to reshore the Switzerland-based GPO, Ascent Health Services, removes a of opacity that facilitated Quallent’s pricing strategies. Ascent had previously negotiated the rebates and discounts for Quallent’s supply agreements outside of U. S. jurisdiction. With Ascent returning to the U. S. and rebates removed from the pricing equation, Quallent loses its ability to function as a margin-capture vehicle. It must compete solely on the basis of genuine supply chain efficiency and net price, stripping away the arbitrage opportunities that defined its early years.

“The vertical integration of PBMs into manufacturing via private labels like Quallent allowed them to become the very entities they were supposed to negotiate against. The settlement forces a decoupling that exposes the true cost of these drugs.”
, FTC Bureau of Competition Statement, February 2026

SECTION 6 of 22: Market Control: The 80 Percent Share Held by the Big Three PBMs

The Oligopoly: 2024-2025 Market Share Data

By the time the Federal Trade Commission filed its administrative complaint in September 2024, the pharmacy benefit management (PBM) sector had calcified into a rigid oligopoly. Verified industry data from 2024 and 2025 confirms that three entities, CVS Caremark, Express Scripts, and Optum Rx, processed approximately 80 percent of all equivalent prescription claims in the United States. This concentration grants these three firms unavoidable gatekeeper status over the pharmaceutical supply chain, dictating access for nearly 270 million Americans.

The internal of this “Big Three” triumvirate shifted significantly between 2023 and 2025. While CVS Caremark historically held the largest share, a massive contract realignment in January 2024 propelled Cigna’s Express Scripts to the top position. Express Scripts secured a five-year agreement to manage pharmacy benefits for Centene Corporation, a contract previously held by CVS. This single transaction transferred approximately 20 million lives and catapulted Express Scripts’ market share from 23 percent in 2023 to 30 percent in 2024.

Table 6. 1: Big Three PBM Market Share Shift (2023, 2025)

PBM Entity	Parent Company	2023 Market Share	2024 Market Share	2025 Status
Express Scripts	The Cigna Group	23%	30%	Market Leader
CVS Caremark	CVS Health	34%	27%	Second Largest
Optum Rx	UnitedHealth Group	22%	23%	Third Largest
Combined Share	N/A	79%	80%	Dominant Oligopoly

Vertical Integration as a Force Multiplier

The FTC’s complaint emphasizes that the raw market share of these PBMs is amplified by their vertical integration with the nation’s largest health insurers. This corporate structure creates a closed loop where the entity negotiating drug prices also owns the insurance plan paying for them.

• The Cigna Group: Owns Express Scripts (PBM) and Cigna Healthcare (Insurer).
• CVS Health: Owns CVS Caremark (PBM) and Aetna (Insurer).
• UnitedHealth Group: Owns Optum Rx (PBM) and UnitedHealthcare (Insurer).

This integration allows the Big Three to use their dual roles to steer patients toward high-rebate drugs. According to the FTC’s September 2024 filing, this structure creates “conglomerates” that are incentivized to disadvantage rival pharmacies and independent manufacturers. The Herfindahl-Hirschman Index (HHI), a standard measure of market concentration used by antitrust regulators, placed the PBM market above 1, 970 in 2024, well past the threshold of 1, 800 that defines a “highly concentrated” marketplace.

The Gatekeeper Effect on Insulin

The practical result of this 80 percent control is the power to exclude. For an insulin manufacturer, failure to secure placement on the formularies of the Big Three is commercially fatal. The FTC investigation revealed that manufacturers like Eli Lilly, Novo Nordisk, and Sanofi were coerced into raising list prices to provide deeper rebates, solely to avoid being locked out of 80 percent of the U. S. market.

“The dominant PBMs can frequently exercise significant control over the cost and availability of drugs… rigging pharmaceutical supply chain competition in their favor.” , Federal Trade Commission Administrative Complaint, Docket No. 9434 (Sept. 2024)

When lower-cost insulin products, such as unbranded biologics or authorized generics, became available between 2015 and 2023, the Big Three frequently excluded them. Because these cheaper alternatives offered lower rebate chance, they were blocked from the formularies that cover the vast majority of American patients. The 2024 Centene contract win by Express Scripts further consolidated this power, placing nearly one-third of all U. S. prescription volume under the control of a single Cigna subsidiary.

SECTION 7 of 22: Patient Financial Harm: The Disconnect Between Rebates and Out-of-Pocket Costs

The “Reverse Insurance” method

The Federal Trade Commission’s administrative complaint against The Cigna Group’s Express Scripts centers on a financial disconnect that systematically disadvantaged insulin-dependent patients between 2015 and 2024. While Express Scripts negotiated aggressive rebates that lowered the net cost of insulin for plan sponsors, these savings rarely materialized for patients at the point of sale. Instead, a “reverse insurance” emerged: patients in the deductible phase or with coinsurance plans paid out-of-pocket costs based on artificially inflated list prices, subsidizing the rebates collected by the PBM.

According to the FTC filing, this pricing structure forced certain patients to pay more for their medication than the insurer’s total net cost. For example, if the list price of a branded insulin vial was $300 the PBM negotiated a rebate reducing the net cost to $50, a patient with a 20 percent coinsurance obligation would pay $60, calculated on the $300 list price, rather than $10 based on the real cost. In high-deductible health plans (HDHPs), the was more severe; patients were frequently responsible for the full $300 list price until their deductible was met, generating a $250 surplus that flowed back to the PBM and plan sponsor rather than the patient purchasing the drug.

The Exclusion of Affordable Alternatives

The complaint alleges that Express Scripts actively blocked access to lower-cost insulin products to protect this rebate revenue. When drug manufacturers introduced “authorized generics”, chemically identical insulin sold at significantly lower list prices, Express Scripts frequently excluded them from standard formularies. These lower-list-price products offered smaller rebates, which threatened the PBM’s retained revenue model.

By 2019, the list price for Humalog had soared to over $274 per vial, a 1, 200 percent increase since 1999. Yet, as list prices climbed, the net price paid by insurers remained flat or even declined due to the deepening rebate pool. The FTC evidence indicates that Express Scripts prioritized high-list, high-rebate products, leaving patients exposed to the inflated sticker price. This practice contributed directly to the rationing emergency, where approximately one in four insulin patients reported underusing their medication due to cost constraints during the complaint period.

Data Analysis: The Gross-to-Net Bubble

The widening gap between what patients paid and what the drugs actually cost the system is known as the “gross-to-net bubble.” The table illustrates the in pricing for a representative long-acting insulin analog during the peak of the rebate arbitrage period.

Table 7. 1: The Insulin Valuation Gap (2014, 2024)

Year	Avg. List Price (WAC)	Est. Net Price (Post-Rebate)	Patient Co-insurance (20% of List)	Patient Overpayment vs. Net %
2014	$280. 00	$130. 00	$56. 00	N/A
2016	$380. 00	$110. 00	$76. 00	69% of Net
2019	$450. 00	$90. 00	$90. 00	100% of Net
2022	$499. 00	$85. 00	$99. 80	117% of Net
2024	$525. 00	$75. 00	$105. 00	140% of Net

“Certain patients, such as patients with deductibles and coinsurance, frequently must pay the unrebated higher list price and do not benefit from rebates at the point of sale. Indeed, they may pay more out-of-pocket for their insulin drugs than the entire net cost of the drug to the commercial payer.” , Federal Trade Commission Administrative Complaint, Docket No. 9434, Paragraph 8.

The “Zero Dollar” Defense vs. Reality

Cigna and Express Scripts have repeatedly defended their model by citing the “Patient Assurance Program,” launched in 2019, which capped insulin copays at $25 for participating plans. While this program provided relief to members, the FTC investigation found it functioned as a “band-aid” that did not address the underlying pricing. The program was optional for plan sponsors, and millions of patients, particularly those in high-deductible plans without the rider or those who were uninsured, remained tethered to the inflated list price.

The February 2026 settlement explicitly validates these allegations of harm. By agreeing to a mandatory “delinking” of rebates from list prices and offering a standard benefit design where patient out-of-pocket costs are based on net prices, Express Scripts conceded that the previous model placed an undue financial load on the sickest patients. The settlement terms require that future savings be passed through to the patient at the pharmacy counter, the arbitrage method that allowed PBMs to profit from the spread between the sticker price and the real price.

The Mechanics of Exclusion: How the “Rebate Wall” Was Built

Between 2015 and 2025, The Cigna Group’s pharmacy benefit manager, Express Scripts, perfected a contractual method known as the “exclusionary formulary.” While publicly marketed as a tool to negotiate lower drug prices, the Federal Trade Commission’s September 2024 administrative complaint alleges that these formularies functioned primarily as use to extract massive rebates from manufacturers. By threatening to cut off access to over 28 million covered lives on its National Preferred Formulary (NPF), Express Scripts forced insulin manufacturers into a “pay-to-play” system where formulary placement was auctioned to the highest bidder, frequently defined not by the lowest net cost, by the largest rebate percentage.

The core of this strategy was the “rebate wall.” If a rival biosimilar or lower-cost insulin attempted to enter the market with a lower list price insufficient rebate volume, Express Scripts could block it from reaching patients. The FTC complaint details that around 2012, PBMs began explicitly threatening to exclude major drugs if manufacturers did not increase rebate payments. This practice escalated throughout the decade, culminating in a market environment where list prices for insulin analogues like Humalog and Lantus rose in lockstep, driven by the PBMs’ demand for higher gross margins to feed their rebate retention models.

The “High-WAC” Preference: Blocking Low-Cost Deflation

A serious component of the FTC’s allegations focuses on the systematic exclusion of “Low-WAC” (Wholesale Acquisition Cost) drugs in favor of “High-WAC” versions. When manufacturers, facing public pressure, introduced identical versions of their insulin products at significantly lower list prices, frequently 50% to 70% cheaper, Express Scripts and its peers frequently excluded these lower-cost options from their standard formularies.

The financial incentive for this counterintuitive behavior is rooted in the rebate arbitrage model. A drug with a $300 list price and a $200 rebate yields a net cost of $100 to the payer, allows the PBM to retain a portion of that $200 rebate (or associated administrative fees calculated as a percentage of the list price). A drug with a $100 list price and no rebate yields the same net cost to the payer zero revenue for the PBM. Consequently, the PBM industry, led by the “Big Three,” erected structural blocks against deflationary pricing.

“One PBM Vice President acknowledged that this strategy allowed the Big Three to continue to ‘drink down the tasty… rebates’ on high list price, highly rebated insulins.” , Federal Trade Commission Administrative Complaint, Docket No. 9434, September 2024.

Case Study: The Semglee Pivot of 2022

The launch of Semglee (insulin glargine-yfgn), the interchangeable biosimilar to Sanofi’s Lantus, provided a clear illustration of this. In 2021, Viatris launched Semglee with two distinct National Drug Codes (NDCs): a branded version with a high list price (comparable to Lantus) and an unbranded version with a list price approximately 65% lower.

January 1, 2022, Express Scripts added the high-list-price branded Semglee to its National Preferred Formulary and excluded the reference product Lantus. While this move was touted as a victory for biosimilars, it preserved the rebate pipeline. By preferring the high-WAC version, Express Scripts ensured that rebate dollars continued to flow, whereas adopting the low-WAC unbranded version would have eliminated the rebate spread. The FTC’s investigation highlighted that this dual-pricing strategy by manufacturers was a direct response to PBM demands for high rebates, rendering the low-cost version inaccessible to patients in major commercial plans.

Financial Impact on the Patient

The exclusion of low-list-price insulins had devastating financial consequences for patients with deductibles or coinsurance. Because patient cost-sharing is calculated based on the list price (WAC) rather than the post-rebate net price, patients were forced to pay a percentage of the artificially inflated price. The table demonstrates the in cost allocation under the exclusionary formulary model versus a hypothetical low-list-price model.

Table 8. 1: Cost Impact of High-Rebate vs. Low-List Price Formulary Strategy (Hypothetical Model based on FTC Allegations)

Cost Component	High-WAC Strategy (Preferred by PBM)	Low-WAC Strategy (Excluded by PBM)
List Price (WAC)	$300. 00	$100. 00
PBM Rebate Negotiated	$200. 00 (66%)	$0. 00 (0%)
Net Cost to Plan	$100. 00	$100. 00
Patient Coinsurance (20% of WAC)	$60. 00	$20. 00
PBM Retained Revenue (Est. 10% of Rebate)	$20. 00	$0. 00
Patient “Overpayment”	$40. 00	$0. 00

2024-2025: The Persistence of Exclusionary Tactics

even with the intense scrutiny leading up to the 2026 settlement, Express Scripts continued to use exclusionary tactics through the 2025 plan year. The 2025 National Preferred Formulary excluded several insulin products, including Basaglar (another insulin glargine biosimilar) and the Humalog U-100 vial, in favor of preferred alternatives that maintained the rebate-driven.

also, the strategy evolved beyond insulin. In 2024 and 2025, Express Scripts applied similar exclusionary pressure to the adalimumab (Humira) market. While multiple low-cost biosimilars became available, the PBM’s formulary decisions initially favored versions that offered substantial rebates or were sourced through its own private-label subsidiary, Quallent Pharmaceuticals. This signaled that the “rebate wall” method was not unique to diabetes care was a foundational operational pillar of the PBM business model, one that required federal intervention to.

The Senate Finance Committee’s 2021 bipartisan report had previously identified that PBMs used exclusion lists to pressure manufacturers into “shadow pricing”, raising prices in lockstep to protect rebate positions. The FTC’s 2024 complaint confirmed that this behavior had not abated voluntarily, necessitating the legal action that would eventually lead to the February 2026 settlement requiring the delinking of rebates from list prices.

The Pay-to-Play Ultimatum

By 2015, the negotiation between insulin manufacturers and pharmacy benefit managers had inverted. Historically, buyers leveraged volume to demand lower prices. In the insulin market, yet, The Cigna Group’s Express Scripts, along with its peers Caremark and Optum, leveraged their control over 80 percent of American prescription claims to demand higher list prices. The Federal Trade Commission’s September 2024 administrative complaint details a coercive system where PBMs threatened to exclude life-saving drugs from formularies unless manufacturers like Eli Lilly and Novo Nordisk inflated their sticker prices to fund larger rebates.

The method was blunt. PBMs generated revenue through administrative fees calculated as a percentage of the Wholesale Acquisition Cost (WAC). A higher list price directly translated to higher fees for the PBM, regardless of the net price paid by the insurer. Internal documents by the FTC reveal that when manufacturers proposed lowering list prices to aid patients, PBM executives resisted, warning that such moves would reduce the “rebate yield” required to maintain their contract status. This created a “rebate wall” where a lower-priced drug was financially toxic to the PBM’s business model.

“Addicted to Rebates”

The FTC’s investigation unearthed explicit evidence of this pressure. The complaint quotes a Vice President at Novo Nordisk stating that PBMs were “addicted to rebates,” a dependency that forced manufacturers to artificially hike prices to satisfy the middlemen. In one instance, when a manufacturer attempted to hold the line on price increases, Express Scripts threatened to move their product to a non-preferred tier, a move that would wipe out the drug’s market share overnight. To survive, the manufacturer capitulated, raising the list price to generate the rebate volume demanded by the PBM.

This pressure resulted in “shadow pricing,” where competitors raised prices in lockstep, sometimes within hours of each other, not to increase their own revenue, to maintain the high price floor required by PBM contracts. Between 2012 and 2019, while the list price of common insulins nearly doubled, the net price received by manufacturers actually declined. The surplus was siphoned off by the PBMs.

The Rejection of Authorized Generics

Perhaps the most damning evidence of PBM interference was the systematic rejection of authorized generics. Eli Lilly and Novo Nordisk produced unbranded versions of their own insulins, chemically identical to Humalog and Novolog, at list prices 50 percent lower than the brand-name versions. In a functional market, these cheaper alternatives would have been prioritized. Instead, Express Scripts and other PBMs frequently blocked these low-WAC products from standard formularies.

The reason was mathematical. A $300 vial of insulin with a 50 percent rebate generates $150 in rebate flow and higher administrative fees for the PBM. A $150 authorized generic with no rebate generates zero rebate flow and minimal fees. Consequently, the PBMs protected the high-cost, high-rebate product to preserve their revenue streams, forcing patients with deductibles or coinsurance to pay the inflated list price at the pharmacy counter.

Data: The Price

The following table illustrates the widening gap between what patients were charged (List Price) and what manufacturers actually earned (Net Price) during the peak of this scheme. The difference represents the “gross-to-net bubble” absorbed by PBMs and the supply chain.

Table 9. 1: Humalog U-100 Pricing (2014, 2019)

Year	List Price (WAC)	Net Price (After Rebates)	PBM/Supply Chain Retained Gap
2014	$391. 00	$138. 00	$253. 00
2015	$505. 00	$135. 00	$370. 00
2016	$560. 00	$130. 00	$430. 00
2017	$594. 00	$128. 00	$466. 00
2018	$594. 00	$126. 00	$468. 00
2019	$594. 00	$124. 00	$470. 00

Source: Senate Finance Committee Investigation Data & FTC Administrative Complaint Findings. Prices reflect approximate cost per patient per month or equivalent unit volume.

The 2024 Collapse of the Rebate Wall

The sustainability of this scheme collapsed under regulatory scrutiny. Following the FTC’s aggressive signaling in 2023 and the filing of the administrative complaint in September 2024, the manufacturers moved to the structure they had helped build. Eli Lilly, Novo Nordisk, and Sanofi announced list price cuts of up to 70 percent, crashing the rebate pool. Humalog’s list price, for example, dropped to approximately $66 in 2024.

Express Scripts’ February 2026 settlement with the FTC formalized the end of this era. By agreeing to delink its compensation from list prices, Cigna’s PBM unit admitted, in practice if not in words, that the prior model was untenable. The settlement mandates that Express Scripts must accept the “net cost” model it had spent a decade fighting, closing the loop on a system that had transferred billions of dollars from sick patients to corporate balance sheets.

The Defense: Cigna’s Argument on Premium Reduction via Retained Rebates

The “Sue the Messenger” Strategy

In a marked departure from traditional corporate defense strategies, The Cigna Group’s initial response to the Federal Trade Commission’s scrutiny was not a legal rebuttal a counter-offensive. On September 17, 2024, three days before the FTC filed its administrative complaint, Cigna’s subsidiary Express Scripts filed a federal lawsuit against the agency in the U. S. District Court for the Eastern District of Missouri. The suit demanded the retraction of the FTC’s July 2024 interim report on pharmacy benefit managers, characterizing the document as “seventy-four pages of unsupported innuendo” rather than a factual analysis.

Andrea Nelson, Chief Legal Officer for The Cigna Group, publicly described the FTC’s actions as “unconstitutional” and “ideologically driven.” The core of this defense was a procedural argument: Cigna claimed that the Commission had ignored “millions of documents and terabytes of data” provided by the company that demonstrated the deflationary effect of PBM negotiation. By framing the regulator as biased and the report as defamatory, Cigna attempted to delegitimize the FTC’s foundational premise, that PBMs force prices up, before the administrative trial could even commence.

The 95 Percent Pass-Through Metric

Central to Cigna’s economic defense is the “pass-through” metric. Throughout 2024 and 2025, Express Scripts consistently argued that the vast majority of rebate revenue is not retained as profit is transferred directly to plan sponsors, employers, unions, and government entities. In filings and public statements, the company asserted that it passes approximately 95 percent of all rebates, discounts, and price reductions back to its clients.

This figure is the lynchpin of their argument regarding premium reduction. Cigna contends that plan sponsors use these repatriated funds to lower monthly premiums and offset benefit costs for the entire membership pool. By this logic, the high list prices of insulin are not a method for PBM profit-taking, a resource pool harvested to subsidize the in total cost of health coverage. The company argued that eliminating these rebates without a commensurate drop in manufacturer list prices would result in an immediate spike in insurance premiums for millions of Americans.

List Price vs. Net Cost

Cigna’s defense relies heavily on the distinction between “list price” (Wholesale Acquisition Cost) and “net cost.” The company that the FTC’s complaint conflates the two, focusing on the sticker price set solely by drug manufacturers while ignoring the actual price paid by plans after PBM discounts are applied.

In its legal responses, Express Scripts emphasized that it does not set the list price of insulin, pharmaceutical companies do. The defense portrayed the PBM as the only check on manufacturer pricing power. According to Cigna, the “rebate wall” described by the FTC is actually a use tool used to force manufacturers to compete for formulary placement, so driving down the net cost. They internal data showing that while list prices for insulin rose over the decade, the net cost to their commercial clients had remained flat or declined due to aggressive rebate negotiation.

The “Patient Assurance” Shield

To counter the FTC’s allegation that high list prices harm patients at the point of sale, Express Scripts pointed to its “Patient Assurance Program.” Launched prior to the litigation and expanded during the scrutiny period, this program capped out-of-pocket costs for insulin at $25 for eligible members.

Cigna used this program as evidence that it was actively shielding patients from the high list prices set by manufacturers. By capping copays, the company argued it had already solved the affordability emergency for its members, rendering the FTC’s interference unnecessary. They contended that the regulator’s focus on the “unrebated” list price paid by a subset of patients in high-deductible phases ignored the structural protections the PBM had already engineered to prevent such exposure.

Transition to “ClearNetwork” Models

As regulatory pressure mounted in 2025, Cigna its defense by accelerating the rollout of alternative business models. The company highlighted its “ClearNetwork” and “ClearCareRx” options, which use a cost-plus pricing model rather than the traditional rebate-retention structure.

By offering these transparent models, Cigna argued that the market was already self-correcting. They posited that if plan sponsors preferred a world without rebates, they could simply choose these new contract structures. The persistence of the rebate model, they argued, was not due to PBM coercion, because clients actively preferred the rebate checks to subsidize their corporate health spending accounts. This “client choice” argument attempted to shift the responsibility for the rebate system away from the PBM and onto the plan sponsors themselves.

2024-2025 Financial Defense Data

Defense Metric	Cigna/Express Scripts Claim	Strategic Purpose
Rebate Pass-Through	~95% to Plan Sponsors	Refutes claim that PBMs hoard rebate revenue.
Retained Rebate Profit	< $400 Million (Est.)	Minimizes the perceived financial incentive for high list prices.
Insulin Copay Cap	$25 per 30-day supply	Demonstrates patient protection from list price inflation.
Net Cost Trend	Flat or Declining (2020-2024)	that PBM negotiation works even with rising list prices.

“The FTC has taken unconstitutional actions in publishing a report that ignores the evidence provided by our company… and advances a false and damaging narrative.”
, Andrea Nelson, Chief Legal Officer, The Cigna Group (September 17, 2024)

Political Integration: The Role of TrumpRx in the Express Scripts Consent Order

The February 4, 2026, settlement between the Federal Trade Commission (FTC) and The Cigna Group’s Express Scripts introduced a regulatory method: the mandatory integration of a government-run direct-to-consumer marketplace into a private pharmacy benefit manager’s (PBM) benefit design. This provision, explicitly detailed in the consent order, requires Express Scripts to provide “covered access” to TrumpRx. gov, the federal drug pricing portal launched on February 5, 2026. Unlike previous settlements that focused solely on monetary fines or behavioral prohibitions, this agreement forces a structural merger between the Trump Administration’s “Most-Favored-Nation” (MFN) pricing initiative and the commercial PBM infrastructure.

The “Covered Access” method

The core of this political integration lies in the “Covered Access” clause of the consent order. Historically, patients who purchased medications outside of their insurance plan, using cash-pay discount cards or direct-to-consumer sites, could not apply those expenditures toward their annual insurance deductibles. This “accumulator adjustment” practice trapped patients within the PBM’s high-list-price ecosystem. The February 2026 settlement this barrier for Express Scripts enrollees. Under the new terms, Express Scripts must credit out-of-pocket costs incurred through TrumpRx. gov toward a member’s deductible and out-of-pocket maximums. This regulatory forcing function imports the government-negotiated MFN prices directly into Cigna’s commercial plans, bypassing the rebate-driven list prices that the FTC’s September 2024 complaint alleged were artificially inflated.

“The FTC’s settlement with Express Scripts… delivers significant wins for the broader Trump-Vance healthcare agenda, including… paving the way for Americans to participate fully in TrumpRx.”
, Andrew N. Ferguson, FTC Chairman, February 4, 2026.

Timeline of Executive Pressure (2025, 2026)

The integration of TrumpRx into the Express Scripts settlement was the culmination of a ten-month campaign of executive pressure that reshaped the FTC’s enforcement strategy. Following the dismissal of FTC Chair Lina Khan in January 2025 and the subsequent termination of Democratic commissioners in March 2025, the Commission’s leadership pivoted from a strategy of “breaking up” PBMs to one of “integrating and regulating” them under the new administration’s policy framework. This shift was accelerated by two key executive actions:

Date	Executive Action	Impact on PBM Negotiations
May 12, 2025	Executive Order 14297: “Delivering Most-Favored-Nation Prescription Drug Pricing”	Established the legal framework for the U. S. government to demand international reference pricing from manufacturers, creating the inventory for TrumpRx.
October 1, 2025	Tariff Threat on Imported Branded Drugs	President Trump threatened a 100% tariff on pharmaceutical imports, forcing manufacturers like Eli Lilly and Novo Nordisk to sign MFN deals and agree to the TrumpRx distribution model.
February 4, 2026	FTC vs. Express Scripts Settlement	Codified the requirement for PBMs to accept TrumpRx pricing, capping insulin costs at the negotiated $35 rate for commercial plan members.

the Rebate Wall

The political integration of TrumpRx addresses the “rebate arbitrage” method by introducing a transparent price floor. The settlement requires Express Scripts to offer a “standard option” to plan sponsors that prioritizes net cost over rebate volume. With TrumpRx offering insulin products like NovoLog and Tresiba at a flat $35 per month (as secured in the November 2025 agreements with manufacturers), Express Scripts can no longer justify the exclusion of these lower-cost versions in favor of high-list-price alternatives that generate rebates. The FTC estimates this structural shift reduce patient out-of-pocket costs for insulin and related therapies by approximately $7 billion over the decade. By tethering the PBM’s formulary compliance to the federal portal, the consent order use Express Scripts’ own infrastructure to distribute the administration’s negotiated price concessions.

The “Trump-Vance” FTC Agenda

The settlement signals a departure from traditional antitrust remedies. FTC Chairman Andrew N. Ferguson, appointed by President Trump, framed the agreement not just as a correction of market failures as an extension of the “Trump-Vance healthcare agenda.” This method use the administrative state to enforce price transparency and “reshore” business practices. The consent order mandates that Express Scripts disclose the net price of drugs, including the value of all rebates and fees, to plan sponsors, aligning private market operations with the transparency standards of the TrumpRx portal. This synchronization ensures that the “Most-Favored-Nation” prices secured by the White House are not theoretical benchmarks are operationally into the transaction flow of the nation’s second-largest PBM.

SECTION 12 of 22: Procedural Timeline: The 2025 Legal Stays and the route to Resolution

The Counter-Litigation Strategy: Early 2025

The procedural trajectory of FTC Docket No. 9434 was immediately complicated by an aggressive legal counter-offensive launched by the respondent pharmacy benefit managers (PBMs). Following the Commission’s September 2024 administrative complaint, The Cigna Group, alongside co-respondents CVS Caremark and Optum Rx, initiated federal lawsuits challenging the constitutionality of the FTC’s in-house adjudication process. By January 2025, this adversarial posture intensified when Cigna filed a defamation suit against the FTC. The claim targeted the Commission’s interim report on PBM practices, released earlier that month, which Cigna characterized as “unfair, biased, erroneous and defamatory.”

These external federal filings created a bifurcated legal track: while the administrative proceeding moved forward under the FTC’s internal rules, the respondents simultaneously sought to invalidate the Commission’s authority in Article III courts. This strategy slowed the discovery phase, as Cigna and its peers argued that the administrative tribunal absence jurisdiction while the constitutional questions remained unresolved.

The April 2025 Procedural Freeze

The administrative proceedings ground to a complete halt in the second quarter of 2025 due to an disruption in the Commission’s leadership structure. On April 14, 2025, the FTC issued a sua sponte order staying all proceedings in Docket No. 9434. The official record a “absence of participating commissioners” necessary to oversee the adjudication.

This procedural paralysis resulted directly from the executive overhaul of the agency following the January 2025 presidential inauguration. The removal of two sitting commissioners, paired with the recusal of remaining members from specific enforcement actions, left the Commission without the quorum required to rule on dispositive motions. For nearly six months, the case remained in administrative limbo. During this period, no evidentiary hearings were held, and the strict deadlines governing FTC administrative trials were suspended indefinitely.

The “TrumpRx” Pivot and Resumption

The stay was lifted in October 2025, following the confirmation of new commissioners and the stabilization of the agency’s leadership. yet, the resumption of the case marked a distinct shift in strategy for The Cigna Group. While CVS Caremark and Optum Rx continued to litigate the constitutional merits of the case, Express Scripts signaled a willingness to engage in settlement discussions that aligned with the new administration’s healthcare agenda.

By late 2025, negotiations had moved beyond the narrow scope of insulin pricing. The discussions began to incorporate broader structural remedies, including the integration of the administration’s “TrumpRx” direct-to-consumer initiative. This pivot transformed the nature of the resolution from a simple antitrust penalty into a regulatory restructuring of Cigna’s PBM operations. The inclusion of the “TrumpRx” framework, which required PBMs to offer a cash-discount option counting toward deductibles, became a central condition for resolving the administrative complaint without a trial.

The January 2026 Suspension

The route to the final settlement was formalized on January 26, 2026, when the FTC filed a motion to withdraw the matter from adjudication specifically regarding The Cigna Group. This filing separated Express Scripts from the other two respondents, severing the case. The motion requested a 14-day suspension to finalize the details of a consent order.

The suspension allowed the parties to codify the terms that would be announced days later: the delinking of rebates from list prices, the reshoring of the Swiss-based Ascent Health Services, and the $7 billion consumer savings commitment. While the litigation against CVS and UnitedHealth Group continued, Cigna’s exit from the docket concluded a sixteen-month procedural saga that transitioned from aggressive counter-litigation to a collaborative regulatory settlement.

Table 12. 1: Procedural Milestones in FTC Docket No. 9434 (2024-2026)

Date	Event	Significance
September 20, 2024	Administrative Complaint Filed	FTC formally charges the “Big Three” PBMs with unfair methods of competition regarding insulin pricing.
November 12, 2024	Constitutional Countersuits	Respondents file federal suits challenging the FTC’s in-house adjudication authority.
January 14, 2025	Cigna Defamation Suit	Cigna sues the FTC over its interim PBM report, alleging bias and factual errors.
April 14, 2025	Commission Stay Issued	Proceedings paused due to absence of participating commissioners following executive leadership changes.
October 2025	Stay Lifted	Administrative proceedings resume; Cigna begins separate settlement track involving “TrumpRx” integration.
January 26, 2026	Motion to Withdraw	FTC suspends case against Cigna/Express Scripts to finalize consent agreement.
February 4, 2026	Settlement Finalized	Express Scripts agrees to structural reforms; case continues against CVS and Optum.

“The FTC paused its proceedings in April 2025 due to a absence of participating commissioners before lifting the motion to stay…, the FTC withdrew the matter from adjudication for Express Scripts.”
, Becker’s Payer problem, February 4, 2026

The February Schism: Breaking the Oligopoly’s Phalanx

On February 4, 2026, the unified defense front of the “Big Three” pharmacy benefit managers fractured. For nearly eighteen months following the Federal Trade Commission’s September 2024 administrative complaint, The Cigna Group (Express Scripts), CVS Health (Caremark), and UnitedHealth Group (OptumRx) maintained a coordinated legal strategy. They jointly argued that the FTC’s claims of insulin price inflation were factually incorrect and constitutionally overreaching. This phalanx collapsed when Cigna entered into a consent order with the commission, agreeing to fundamentally restructure its rebate processing method and repatriate its Swiss-based group purchasing organization, Ascent Health Services.

The in strategy highlights a serious calculation by Cigna’s leadership: the regulatory risk to its Evernorth Health Services division had become an existential threat to its stock valuation and merger ambitions. While Express Scripts chose to settle, accepting strict federal oversight to preserve its operational continuity, CVS Caremark and OptumRx elected to continue litigation. These two competitors are doubling down on administrative law defenses, betting that federal courts invalidate the FTC’s aggressive interpretation of “unfair methods of competition” under Section 5 of the FTC Act.

Comparative Legal Postures: February 2026

The table outlines the immediate strategic between the three major PBMs as of March 2026.

Entity	Parent Company	Legal Status (Mar 2026)	Primary Strategic Rationale	Key Concession/Defense
Express Scripts	The Cigna Group	Settled (Consent Order)	Mitigate reputational damage; protect Evernorth valuation; stabilize stock for M&A.	Agreed to delink rebates from list prices; reshore Ascent Health Services from Switzerland to U. S.
CVS Caremark	CVS Health	Litigating	Defend the integrated retail-insurance-PBM model; challenge FTC jurisdiction.	Asserts rebates lower premiums; cites SEC v. Jarkesy to challenge FTC tribunal authority.
OptumRx	UnitedHealth Group	Litigating	Protect the Emisar GPO structure; use massive legal war chest.	” drug lists” already cap insulin; claims FTC ignores manufacturer pricing power.

The Constitutional Shield: Why Caremark and OptumRx Fight

CVS Health and UnitedHealth Group have anchored their continued resistance in recent Supreme Court precedents that weaken federal agency power. Specifically, their legal teams are leveraging the 2024 SEC v. Jarkesy decision, which limited the use of internal administrative tribunals for seeking monetary penalties. By refusing to settle, Caremark and OptumRx are challenging the FTC’s constitutional authority to adjudicate the case in-house rather than in a federal district court.

Filings from late 2025 indicate that both companies are preparing to that the FTC’s definition of “coercion”, the claim that PBMs force manufacturers to raise list prices, is economically incoherent. OptumRx’s defense relies on data showing that net prices for insulin have declined for plan sponsors, arguing that the “list price inflation” by the FTC is a manufacturer decision, not a PBM requirement. By continuing to litigate, they aim to force the FTC to prove intent to harm competition, a higher evidentiary bar than the “unfairness” standard used in the settlement negotiations.

Cigna’s Calculation: The Ascent Liability

Cigna’s decision to break ranks appears driven by the specific vulnerabilities of its group purchasing organization, Ascent Health Services. Unlike CVS’s Zinc or UnitedHealth’s Emisar, Ascent was domiciled in Schaffhausen, Switzerland. This offshore structure attracted intense scrutiny from both the FTC and congressional investigators, who characterized it as a “black box” designed to evade U. S. regulatory oversight.

The settlement terms require Cigna to redomicile Ascent to the United States and grant the FTC audit rights over its rebate flows. For Cigna, this concession was likely the price of survival. Continued litigation would have exposed Ascent’s internal communications and financial transfers to public discovery, chance revealing tax strategies or rebate retention rates that could trigger further liability. By settling, Cigna seals the “Swiss Loophole” voluntarily, preventing a chance more damaging court-ordered of its GPO operations.

“The settlement enables us to keep moving forward… This is a meaningful step toward affordability for millions of families.”
, Express Scripts Statement, February 5, 2026

Financial of the Split

The creates a temporary competitive imbalance. Express Scripts must operate under a “delinked” model where it charges flat fees rather than retaining a percentage of the list price. This theoretically reduces its immediate profit margins on insulin offers clients a transparent, “audit-proof” contract model.

Conversely, CVS Caremark and OptumRx retain their traditional rebate-based revenue streams for the duration of the litigation, which could drag on into 2027. yet, they face the accumulation of massive legal fees and the risk of a sudden, catastrophic judgment if the courts side with the FTC. Market analysts suggest that if Express Scripts successfully transitions its client base to the new transparent model without losing profitability, it could force CVS and UnitedHealth to capitulate, not due to legal defeat, due to market pressure from plan sponsors demanding the same transparency.

The method of Extraction: Direct and Indirect Remuneration

While the public focus of the Federal Trade Commission’s complaint against The Cigna Group centered on the inflated list prices of insulin, a parallel financial method was quietly the nation’s independent pharmacy network: Direct and Indirect Remuneration (DIR) fees. These fees, frequently described by dispensers as “clawbacks,” function as a retroactive tax on pharmacies, allowing Pharmacy Benefit Managers (PBMs) like Express Scripts to recoup a percentage of the reimbursement months after a prescription is filled.

The of this extraction is mathematically. According to data from the Centers for Medicare & Medicaid Services (CMS), retroactive DIR fees increased by 107, 400 percent between 2010 and 2020. For independent pharmacies operating on razor-thin margins, frequently dispensing insulin at a net loss, these fees transformed the business of healthcare into a struggle for solvency. The fees were frequently tied to unclear “performance metrics” that pharmacies could neither predict nor control, allowing PBMs to arbitrarily adjust their own profit margins at the expense of the dispenser.

The 2024-2025 Liquidity emergency: The “DIR Hangover”

The structural violence of this system culminated in a liquidity emergency known within the industry as the “DIR Hangover,” which struck with full force in early 2024 and through 2025. Following a CMS rule change intended to increase transparency, PBMs were required to move DIR fees to the point of sale (POS) starting January 1, 2024. While this theoretically ended the unpredictability of retroactive clawbacks, the transition period created a fatal financial trap.

Throughout 2024, independent pharmacies faced a “double whammy”: they were forced to pay the retroactive DIR fees from 2023 prescriptions while simultaneously accepting lower upfront reimbursement rates for 2024 prescriptions, as the new POS fees were deducted immediately. This cash flow vacuum decimated reserves.

NCPA January 2025 Survey Data:
“80. 3 percent of independent pharmacists said the financial health of their business declined in 2024, with 48. 6 percent reporting a significant decline. 30. 3 percent stated they are considering closing their business in Calendar Year 2025.”

Reimbursement Acquisition Cost

The FTC’s investigation, by its July 2024 Interim Report, validated a long-standing complaint from independent dispensers: PBMs frequently reimburse pharmacies at rates the actual cost to purchase the drug. This practice is particularly acute with high-list-price maintenance medications like insulin.

Data from the National Community Pharmacists Association (NCPA) in January 2025 revealed that 40. 8 percent of independent pharmacists were paid the National Average Drug Acquisition Cost (NADAC) on more than 40 percent of the Medicare Part D prescriptions they filled. For insulin, a life-sustaining drug with high inventory costs, this underwater reimbursement model meant that every vial dispensed was a financial penalty for the pharmacy.

The in reimbursement rates further cemented the competitive advantage of PBM-owned pharmacies. The FTC’s July 2024 report confirmed that PBMs, including Express Scripts, systematically reimbursed their own affiliated pharmacies at higher rates than independent competitors for the exact same medications. This “spread” allowed Cigna’s vertical stack to extract value at both ends: charging plan sponsors high prices for insulin while paying independent pharmacies -market rates to dispense it.

The Casualty Count: Pharmacy Deserts and Closures

The cumulative effect of DIR fees and -cost reimbursement has been a rapid acceleration of pharmacy closures, creating “pharmacy deserts” in communities. In the quarter of 2025 alone, over 300 pharmacies permanently closed their doors, 237 of which were independent retailers.

Metric	Statistic (2024-2025)	Source
Independent Pharmacy Locations	Dropped to 18, 960 (July 2025)	NCPA Digest 2025
Closures in Q1 2025	300+ (237 Independent)	RedSail Technologies Report
Reimbursement NADAC	40. 8% of pharmacies on>40% of scripts	NCPA Jan 2025 Survey
Considered Closing in 2025	30. 3% of owners	NCPA Jan 2025 Survey

These closures are not commercial failures; they represent a severance of healthcare access. The USC-NCPA Pharmacy Access Initiative reported in October 2025 that roughly one in eight neighborhoods in the United States meets the criteria for a pharmacy absence area. When an independent pharmacy closes, patients, particularly those reliant on insulin, are frequently steered toward PBM-owned mail-order services, completing the pattern of market capture.

Regulatory Vindication and the Cost-Plus Mandate

The February 2026 settlement between the FTC and Express Scripts directly addresses this widespread imbalance. As part of the agreement, Express Scripts is mandated to adopt a “cost-plus” reimbursement model for independent pharmacies. This model requires the PBM to reimburse pharmacies based on the actual acquisition cost of the drug plus a fixed professional dispensing fee, outlawing the -cost reimbursement tactics that fueled the closure wave.

While this regulatory intervention arrives too late for the hundreds of pharmacies that shuttered in 2024 and 2025, it the financial engine that allowed PBMs to use DIR fees as a weapon of market consolidation. The shift acknowledges that the solvency of the dispensing network is distinct from the pricing strategies of manufacturers, forcing PBMs to decouple their profit motives from the survival of Main Street pharmacies.

SECTION 15 of 22: Vertical Integration: The Evernorth Health Services Profit Shield

The Financial Engine: Evernorth’s Dominance Over Cigna Healthcare

By the time the Federal Trade Commission (FTC) finalized its settlement with The Cigna Group in February 2026, the corporate structure of the defendant had fundamentally shifted. While Cigna is historically known as a health insurer, its financial filings from 2024 and 2025 reveal that it has transformed into a health services conglomerate with an insurance subsidiary. The engine of this transformation is Evernorth Health Services, the unregulated division that houses Express Scripts (PBM), Accredo (specialty pharmacy), and eviCore (medical benefit management).

The in financial performance between the two arms is clear. In the full year 2024, The Cigna Group reported total revenues of $247. 1 billion, a 27 percent increase from the previous year. This growth was not driven by insurance premiums by the pharmacy and services division. Evernorth’s Pharmacy Benefit Services alone generated $111. 8 billion in adjusted revenue for 2024, a 46 percent jump year-over-year. In contrast, Cigna Healthcare, the regulated insurance arm, saw its adjusted revenues contract by approximately 18 percent in comparable quarters following the divestiture of its Medicare business to Health Care Service Corporation (HCSC).

This revenue imbalance is not an operational detail; it is the structural foundation of the “profit shield.” By housing high-margin pharmacy and specialty services within Evernorth, Cigna can capture profits outside the regulatory perimeter that constrains its insurance business.

The Medical Loss Ratio (MLR) Arbitrage

The core incentive for vertical integration in the insulin market lies in the Affordable Care Act’s Medical Loss Ratio (MLR) requirement. Federal law mandates that insurers spend at least 80 to 85 percent of premium dollars on medical care or quality improvement. If they spend less, they must rebate the difference to policyholders. This cap limits the profit margins of Cigna Healthcare.

Evernorth serves as a method to bypass this cap. When Cigna Healthcare pays Express Scripts or Accredo for insulin, that payment is classified as a “medical cost,” helping the insurance arm meet its 85 percent MLR threshold. yet, the profit margin on that insulin, generated through rebate retention, spread pricing, and dispensing fees, is captured by Evernorth. Because Evernorth is a services company, not an insurer, it is not subject to the MLR cap.

Financial data from late 2025 confirms the efficacy of this shield. In the third quarter of 2025, Cigna Healthcare reported a Medical Care Ratio (MCR) of 84. 8 percent, squeezing its insurance margins. Simultaneously, Evernorth posted adjusted income from operations of over $2. 3 billion for the quarter. The vertical structure allows the parent company to retain the “spread” on insulin prices within the unregulated entity while reporting higher medical costs in the regulated one.

Accredo: The Specialty Pharmacy Funnel

The FTC’s administrative complaint highlighted how this vertical stack incentivizes the use of high-list-price drugs. The method extends beyond the PBM to the specialty pharmacy, Accredo. As part of Evernorth, Accredo specializes in dispensing complex, high-cost medications. In 2024, Evernorth’s Specialty and Care Services division, which includes Accredo, grew its revenue by 18 percent to $90. 3 billion.

For insulin, the vertical integration creates a closed loop. Express Scripts creates the formulary, frequently designating high-list-price insulins as “preferred” due to the rebates they generate. Plan members are then frequently steered toward Accredo for fulfillment. This steering ensures that Cigna captures revenue at every stage of the transaction:

Table 15. 1: The Vertical Revenue Capture pattern for Insulin (2024-2025)

Stage	Entity	Revenue method	Regulatory Impact
Formulary Design	Express Scripts (PBM)	Rebate negotiation with manufacturers	Unregulated (Pre-2026 Settlement)
Insurance Coverage	Cigna Healthcare (Payer)	Premium collection	Capped by MLR (80/85%)
Fulfillment	Accredo (Specialty Pharmacy)	Dispensing fees & spread pricing	Unregulated Service Revenue
Group Purchasing	Ascent Health Services (GPO)	Volume-based admin fees	Offshore (Pre-2026 Settlement)

The FTC’s Structural Challenge

The FTC’s September 2024 complaint specifically targeted the incentives created by this consolidation. The agency alleged that the “Big Three” PBMs, including Express Scripts, used their vertical integration to rig the supply chain. By favoring high-list-price insulins, they increased the dollar value of the rebates and fees flowing into their service arms.

The complaint noted that while PBMs argued they passed rebates to plan sponsors, the vertical structure allowed them to redefine “costs.” If Express Scripts charges Cigna Healthcare a high price for insulin, Cigna Healthcare “pays” it, satisfying the MLR. The money simply moves from the left pocket (Insurance) to the right pocket (Evernorth), the high list price remains the load of the patient in the deductible phase.

The February 2026 settlement directly disrupts this internal flow. By requiring Express Scripts to delink rebates from list prices and mandating that patient out-of-pocket costs be based on net cost, the settlement removes the primary fuel, inflated list prices, that powered the Evernorth profit shield.

2025 Financial Defense and Future Outlook

Throughout the investigation, Cigna defended its structure by pointing to its “Patient Assurance Program,” which capped insulin costs at $25 for eligible members. yet, the FTC argued that such programs were band-aids that did not address the underlying list price inflation driven by the vertical incentives.

Following the settlement, Cigna has signaled a strategic pivot. In its guidance for 2026, the company projected continued growth for Evernorth acknowledged the transition to a “rebate-free” model. Executives stated in the Q4 2025 earnings call that they expect the profit profile to remain “broadly similar” by shifting to flat administrative fees. while the method of rebate arbitrage has been dismantled, the vertical integration strategy remains the company’s central method for value capture.

SECTION 16 of 22: Historical Data: The 1, 200 Percent Insulin List Price Surge 2012-2025

The Federal Trade Commission’s administrative complaint against The Cigna Group’s Express Scripts is grounded in a specific, verifiable historical dataset: the between the list price (Wholesale Acquisition Cost, or WAC) of insulin and its net price between 2012 and 2025. While the “1, 200 percent increase” figure by the Senate Committee on Health, Education, Labor, and Pensions (HELP)

The following section details the specific method by which Express Scripts managed the entry of Semglee, the interchangeable biosimilar insulin, into its formulary.

SECTION 17 of 22: Case Study: The Exclusion of Semglee in Favor of High-Cost Lantus

The Biosimilar Firewall: 2020, 2021

The arrival of Semglee (insulin glargine-yfgn) in the United States market presented the significant test of the pharmacy benefit management industry’s willingness to embrace lower-cost biosimilars over high-rebate reference biologics. Approved by the FDA in June 2020 as a biosimilar to Sanofi’s blockbuster Lantus, Semglee offered a clinically equivalent alternative at a significantly reduced wholesale acquisition cost (WAC). For the 18 months following its initial approval, yet, the drug faced a formidable “rebate wall” erected by the incumbent manufacturer and fortified by PBM incentives.

Between June 2020 and late 2021, Express Scripts maintained Lantus as the preferred long-acting insulin on its National Preferred Formulary (NPF). During this period, Sanofi paid substantial rebates to Express Scripts to secure this exclusivity, blocking the lower-priced biosimilar from gaining market share. The financial logic was consistent with the “rebate arbitrage” model: while Semglee carried a lower sticker price, it initially absence the volume to generate rebate revenue comparable to the mature Lantus contract. Consequently, patients remained locked into the higher-list-price product, with their deductibles and coinsurance calculated based on Lantus’s inflated WAC, which exceeded $280 per vial in 2020, rather than the net price negotiated by the PBM.

The Interchangeability Pivot and the Two-Price Strategy

The shifted in July 2021 when the FDA granted Semglee “interchangeable” status, allowing pharmacists to substitute it for Lantus without a new prescription. This regulatory milestone forced PBMs to address the biosimilar directly. In response, Viatris (the manufacturer of Semglee) executed a dual-pricing strategy designed specifically to navigate the PBM rebate system. The company launched two identical versions of the drug:

Table 17. 1: Viatris Dual-Pricing Structure for Insulin Glargine-yfgn (2021 Launch)

Product Version	Wholesale Acquisition Cost (WAC)	Rebate Status	Target Audience
Semglee (Branded)	~$269. 38 (per 5-pack pens)	High Rebate Eligible	PBM Formularies
Insulin Glargine (Unbranded)	~$98. 65 (per 5-pack pens)	Low/No Rebate	Cash Pay / Non-PBM Markets

This pricing bifurcation exposed the PBM industry’s preference for high list prices. The unbranded version, priced 65% lower than Lantus, offered immediate savings to the healthcare system and patients paying out-of-pocket. yet, adopting the low-cost version would have eliminated the rebate spread that Express Scripts relied upon for revenue.

The 2022 Formulary Decision: Preferring the High-Cost Option

In October 2021, Express Scripts announced a major formulary update for the 2022 benefit year. The PBM declared it would exclude Lantus from its National Preferred Formulary in favor of Semglee. While public relations statements touted this as a move to “drive greater affordability,” the mechanics of the decision revealed a continued adherence to rebate-driven economics.

Express Scripts selected the high-list-price branded Semglee as the preferred agent, rejecting the identical, low-list-price unbranded version. By choosing the ~$269 product over the ~$99 product, Express Scripts preserved its ability to extract rebates from Viatris. The FTC’s September 2024 administrative complaint specifically cites this behavior, alleging that the “Big Three” PBMs systematically excluded lower-list-price insulins to protect their revenue streams.

“We have advocated for more than a decade for a safe and pathway to bring biosimilars to market… This important designation is another milestone toward a pathway for the full adoption of biosimilars.”
, Amy Bricker, President of Express Scripts (October 2021 Press Release)

even with this rhetoric, the decision to favor the high-WAC version meant that patients with high-deductible health plans or coinsurance requirements saw little to no reduction in their point-of-sale costs. A patient paying 20% coinsurance on the preferred Semglee would owe approximately $54 per box, whereas the full list price of the excluded unbranded version was roughly $99. Had Express Scripts preferred the low-cost version, the same patient’s coinsurance would have dropped to roughly $20, or they could have purchased it outright for less than the cost of their deductible payments.

Financial of the “Rebate Wall”

The exclusion of the low-cost unbranded insulin glargine demonstrates the “rebate wall” method. If Express Scripts had switched to the low-cost version, they risked triggering “make whole” clauses in their legacy contracts with Sanofi or failing to meet volume guarantees required to earn rebates on other products in the same therapeutic basket. also, the administrative fees collected by PBMs are frequently calculated as a percentage of the WAC; a 65% reduction in the list price would have resulted in a corresponding collapse in administrative fee revenue.

Data from the FTC investigation indicates that the retention of high list prices for insulin generated billions in excess costs for American patients between 2015 and 2023. In the specific case of Semglee, the PBM’s choice neutralized the deflationary pressure the biosimilar was intended to create. It was not until Sanofi voluntarily slashed the price of Lantus by 78% ( January 2024), a move largely forced by legislative pressure and the pending FTC litigation, that the list price gap began to close.

Regulatory and 2026 Settlement

The “Semglee maneuver” became a central exhibit in the FTC’s case against the PBM oligopoly. The agency argued that by denying patients access to the low-WAC unbranded options, Express Scripts engaged in unfair methods of competition. This practice is directly addressed in the February 2026 settlement, which mandates that Express Scripts must no longer exclude lower-list-price drugs in favor of identical high-list-price versions on its standard formularies.

The settlement forces a decoupling of rebates from formulary placement, theoretically ending the era where a $269 biosimilar is preferred over its $99 twin. yet, for the years 2022 through 2025, the preference for high-cost Semglee stands as a definitive example of how PBM incentives can invert the economics of generic and biosimilar competition, converting a tool for cost savings into a method for rebate preservation.

The Statutory Basis: Section 5 of the FTC Act

The Federal Trade Commission’s administrative complaint against The Cigna Group’s Express Scripts, filed in September 2024, represents a definitive application of the agency’s “standalone” authority under Section 5 of the FTC Act. Unlike traditional antitrust lawsuits that rely on the Sherman Act (targeting monopolies or conspiracies) or the Clayton Act (targeting mergers and price discrimination), this action invokes the broader mandate of Section 5, which prohibits “unfair methods of competition” (UMC) and “unfair or deceptive acts or practices” (UDAP).

By utilizing this statute, the FTC circumvents the rigorous “rule of reason” standard frequently required in Sherman Act cases, which proving market power and defining relevant markets with granular economic precision. Instead, the Commission’s legal theory posits that the rebate-driven business model itself constitutes a coercive method that distorts competitive incentives, regardless of whether it fits the strict definition of a monopoly under 19th-century antitrust laws.

Reviving the “Standalone” Authority

The legal framework for this complaint is grounded in the FTC’s November 2022 Policy Statement Regarding the Scope of Unfair Methods of Competition. This document, issued under Chair Lina Khan, formally rescinded the agency’s 2015 policy that had voluntarily restricted Section 5 enforcement to conduct violating the Sherman or Clayton Acts. The 2022 Statement restored the agency’s Congressional mandate to arrest anticompetitive incipiency, practices that may not yet constitute a full-blown monopoly violate the “spirit” of antitrust laws.

In the context of pharmacy benefit managers (PBMs), the FTC applies this restored authority to classify “rebate arbitrage” as an unfair method of competition. The complaint that Express Scripts and its peers engaged in conduct that is “coercive, exploitative, or exclusionary.” Specifically, the legal filing asserts that by conditioning formulary access on high rebates, which high list prices, PBMs created a market structure where competition occurs over rebate size rather than net price. This inversion is framed not as aggressive business, as a structural that prevents lower-cost drugs from competing on the merits of affordability.

The “Unfair Acts or Practices” Prong

Beyond competition, the complaint invokes the consumer protection side of Section 5, alleging “unfair acts or practices.” Under Section 5(n) of the FTC Act, an act is unfair if it causes substantial injury to consumers, is not reasonably avoidable by consumers, and is not outweighed by countervailing benefits to consumers or competition.

Table 1: The Three-Part Test for Unfairness (Section 5(n)) Applied to PBMs

Legal Element	FTC Allegation Against Express Scripts
Substantial Injury	Patients pay deductibles and coinsurance based on inflated list prices (e. g., $300 for insulin) rather than the net price (e. g., $30), resulting in millions of dollars in excess out-of-pocket costs.
Not Reasonably Avoidable	Patients cannot choose their PBM or the formulary design; they are locked into the plan selected by their employer or insurer and must pay the price at the pharmacy counter to receive life-saving medication.
No Countervailing Benefit	The FTC that the “rebate wall” offers no net benefit to the healthcare system, as the rebates are largely retained by PBMs or used to offset premiums in a way that is unclear and inequitable to the sickest patients.

Exclusionary Conduct and Rebate Walls

The core of the “Unfair Methods of Competition” charge lies in the concept of the “rebate wall.” The complaint details how Express Scripts allegedly used its market dominance to threaten manufacturers with exclusion. If a drug maker attempted to lower its list price, the PBM would threaten to remove the drug from the formulary in favor of a competitor to maintain a high list price and pay a larger rebate.

This conduct is legally significant because it creates a barrier to entry for low-cost competitors. For instance, when generic or biosimilar insulins were introduced at significantly lower list prices, they were frequently excluded from top-tier formulary placement. The FTC this is exclusionary because it blocks products that would naturally win in a competitive market (those with lower prices) and artificially props up products that harm consumer welfare (those with inflated prices). Under the 2022 Policy Statement, this “tendency to negatively affect competitive conditions” is sufficient to trigger liability, without the need to prove a specific percentage of market foreclosure as required in Sherman Act litigation.

The Role of Coercion

A serious element of the FTC’s legal theory is the role of coercion in the supply chain. The complaint alleges that manufacturers did not voluntarily raise insulin prices by 1200% between 1999 and 2017 purely for profit, were compelled to do so to satisfy the PBMs’ demand for ever-increasing rebates. This “pay-to-play” shifts the legal culpability. While manufacturers set the list price, the FTC posits that the PBMs constructed the incentive structure that made price inflation a rational need for survival. By controlling access to the patient base (the “lives” covered by Cigna’s insurance arm), Express Scripts held the gatekeeper power to coerce pricing behavior from upstream suppliers.

“The PBMs created a perverse drug rebate system that prioritizes high rebates from drug manufacturers, leading to artificially inflated insulin list prices… This conduct constitutes an unfair method of competition because it distorts the competitive process, incentivizing higher prices rather than lower ones.”
, FTC Administrative Complaint, Docket No. 9434 (September 2024)

Challenging the “Virtual Manufacturer” Defense

The legal framework also scrutinizes the integration of entities like Quallent Pharmaceuticals. By treating Cigna’s private-label subsidiary as a “manufacturer,” the PBM could technically claim it was negotiating with a third party. yet, the FTC’s application of Section 5 disregards these corporate formalities, looking instead at the economic reality. The complaint treats the PBM, the GPO (Ascent Health Services), and the private labeler (Quallent) as a single economic unit engaged in a coordinated strategy to extract rents. This “substance over form” method is characteristic of the agency’s modern interpretation of the FTC Act, which seeks to pierce through complex vertical integration that obscures anticompetitive harm.

for Future Enforcement

The reliance on Section 5 signals a strategic shift in how the U. S. government polices healthcare intermediaries. By avoiding the Sherman Act, the FTC signaled that it does not need to prove that Express Scripts is a “monopoly” in the traditional sense, rather that its business practices are “unfair.” This lowers the load of proof for the government and expands the scope of liable conduct. The complaint puts the entire PBM business model, specifically the retention of rebates and spread pricing, on trial, establishing a legal precedent that intermediaries cannot profit by distorting the price signals of the goods they manage.

The Ohio Offensive: “Modern Gangsters” and the Valentine Act

While the Federal Trade Commission assembled its federal administrative case, state-level prosecutors launched aggressive parallel litigation targeting the same rebate structures. The most vociferous of these actions originated in Ohio, where Attorney General Dave Yost filed a landmark antitrust lawsuit on March 27, 2023. Unlike other state actions that broadly targeted the entire pharmaceutical supply chain, Yost’s complaint specifically pharmacy benefit managers, with a primary focus on The Cigna Group’s Express Scripts and its collusion with Prime Therapeutics.

Filed in Delaware County Common Pleas Court, the lawsuit alleged violations of the Valentine Act, Ohio’s strong antitrust statute. Yost’s filing utilized unusually combative language, characterizing PBMs as “modern gangsters” who had “absolutely destroyed transparency.” The complaint detailed how Express Scripts and Prime Therapeutics utilized Ascent Health Services, the Swiss-based group purchasing organization, to share competitively sensitive pricing and rebate information. This method, Yost argued, allowed the entities to fix prices and drive insulin costs from approximately $20 per unit in the late 1990s to between $300 and $700 per unit by 2023.

The Ohio litigation highlighted the specific impact on the state’s 1. 1 million diabetic residents. Yost’s investigation uncovered that the “pay-to-play” rebate system forced manufacturers to artificially list prices to secure formulary placement, a practice that directly penalized patients at the point of sale. Although the suit began in state court, the defendants successfully maneuvered to remove the case to federal jurisdiction. By late 2025, the Ohio action had been consolidated into the massive In re Insulin Pricing Litigation multidistrict litigation (MDL No. 3080) in the District of New Jersey, joining the “State Attorney General Track” alongside similar suits from other jurisdictions.

The California Campaign: Unfair Competition and the Rebate Trap

Preceding the Ohio filing, California Attorney General Rob Bonta opened a western front against the PBM oligopoly on January 12, 2023. Bonta’s lawsuit, filed in Los Angeles County Superior Court, targeted both the three major insulin manufacturers (Eli Lilly, Novo Nordisk, Sanofi) and the “Big Three” PBMs, including Express Scripts. The complaint alleged violations of California’s Unfair Competition Law, asserting that these entities engaged in a “rebate trap” that aggressively hiked the cost of life-saving medication.

The California Department of Justice emphasized the of the emergency, noting that 3 million adults in the state, roughly 10 percent of the adult population, are diagnosed with diabetes. The lawsuit argued that the PBMs’ demand for ever-increasing rebates necessitated the inflation of list prices, a pattern that rendered insulin unaffordable for uninsured and underinsured Californians. Bonta sought not only civil penalties also restitution for residents who had been overcharged for insulin over the preceding decade.

The procedural history of the California case reflects the intense legal trench warfare between states and Cigna. Initially removed to federal court, the case was remanded back to state court, only for defendants to appeal the remand to the Ninth Circuit. In June 2024, a Los Angeles Superior Court judge sustained demurrers regarding the statute of limitations, forcing the state to amend its complaint. yet, by December 30, 2024, the litigation trajectory shifted decisively; the case was transferred to the District of New Jersey, merging into the same federal MDL as the Ohio action.

Consolidation: The MDL No. 3080 Juggernaut

By the close of 2025, the individual state actions by Ohio, California, and others had largely coalesced into In re Insulin Pricing Litigation (MDL No. 3080). Presided over by Judge Brian R. Martinotti, this multidistrict litigation became the central repository for the nation’s grievances against the insulin pricing scheme. As of December 2025, the docket contained approximately 445 active cases, including those from state attorneys general, municipal governments, and self-funded payers.

Table 19. 1: Key State Attorney General Actions vs. Express Scripts (2023-2025)

State	Filing Date	Key Statute	Primary Allegation	2025 Status
California	Jan 12, 2023	Unfair Competition Law	Deceptive “rebate trap” driving list price inflation.	Transferred to MDL No. 3080 (D. N. J.) in Dec 2024.
Ohio	Mar 27, 2023	Valentine Act (Antitrust)	Collusion via Ascent Health Services to fix prices.	Active in MDL No. 3080; State AG Track.
Arkansas	July 2023	Deceptive Trade Practices	Unconscionable pricing of insulin products.	Consolidated into MDL No. 3080.
Kentucky	June 2023	Consumer Protection Act	Excessive pricing and rebate manipulation.	Consolidated into MDL No. 3080.

The consolidation of these state actions into a federal MDL created a dual-track threat for Cigna. While the FTC pursued its administrative complaint focused on unfair methods of competition under Section 5 of the FTC Act, the state attorneys general, unified in the District of New Jersey, pursued damages and restitution under state consumer protection and antitrust laws. This pincer movement ensured that even as Cigna negotiated with federal regulators, it remained exposed to billions of dollars in chance liability from the states.

“PBMs are modern gangsters… They were designed to protect and negotiate on behalf of employers and consumers after Big Pharma was criticized for overpricing medications, instead they have absolutely destroyed transparency, scheming in the shadows to control drug prices on all sides of the market.”
, Dave Yost, Ohio Attorney General, Press Statement, March 27, 2023.

The parallel nature of these actions prevented Cigna from isolating its legal defense. Evidence unearthed in the FTC’s investigation regarding the “Swiss Loophole” and rebate arbitrage directly strengthened the states’ arguments in the MDL. Conversely, the aggressive discovery demands from state prosecutors regarding the specific harm to local diabetic populations provided the FTC with granular data to support its broader market manipulation claims.

Investor Analysis: Cigna Stock Stability Following the Non-Monetary Settlement

The capital markets frequently price regulatory risk not by the severity of the allegations, by the certainty of the outcome. For The Cigna Group (NYSE: CI), the trajectory from the Federal Trade Commission’s September 2024 administrative complaint to the February 2026 settlement demonstrates a textbook case of “pricing in” existential threats. While the FTC’s initial filing alleged that Express Scripts inflated insulin prices to subsidize rebates, a claim that theoretically threatened the core revenue model of pharmacy benefit managers (PBMs), Cigna’s stock stability during this eighteen-month period was maintained through aggressive capital allocation and a strategic pivot to service-based revenues.

The “Non-Event” of the Initial Filing

On September 20, 2024, when the FTC formally filed Docket No. 9434, market observers anticipated a volatility spike characteristic of antitrust enforcement actions. Instead, Cigna shares exhibited a counter- resilience. In the trading session immediately following the filing, Cigna stock declined by a mere 0. 6 percent, a statistical deviation indistinguishable from standard daily noise. This muted reaction signaled that institutional investors had already discounted the regulatory overhang. By late 2024, the “PBM transparency” narrative had circulated in Washington for nearly two years. The formal complaint was viewed not as a new catastrophe, as the inevitable crystallization of a known risk. Analysts noted that the market valued the *removal of uncertainty*, even via litigation, over the ambiguous threat of legislative action.

The Buyback Firewall: 2024-2025 Capital Allocation

To counteract the suppression of its valuation multiples during the litigation phase, Cigna deployed a massive capital return program. This strategy functioned as a “buyback firewall,” artificially supporting earnings per share (EPS) and signaling management’s confidence in the company’s solvency even with the federal probe. Between January 2024 and December 2025, Cigna repurchased shares at a pace that outstripped of its managed care peers. In 2024 alone, the company deployed $7. 0 billion toward share repurchases, retiring approximately 20. 9 million shares. This aggressive buyback activity continued into 2025, with an additional $3. 6 billion allocated to repurchases, even as the FTC litigation entered its discovery phase.

Table 1: Cigna Group Capital Deployment During FTC Litigation (2024-2025)

Fiscal Year	Share Repurchases ($Bn)	Dividends Paid ($Bn)	Total Capital Returned ($Bn)	Avg. Shares Retired (Millions)
2024	$7. 0	$1. 6	$8. 6	20. 9
2025	$3. 6	$1. 7	$5. 3	11. 9
Total	$10. 6	$3. 3	$13. 9	32. 8

This capital deployment strategy neutralized the “regulatory discount.” By reducing the share count, Cigna engineered EPS growth that masked the stagnation in valuation multiples. For fiscal year 2025, Cigna reported shareholders’ net income of $6. 0 billion ($22. 18 per share), a sharp recovery from 2024, driven largely by the mathematical use of a shrinking share base.

Evernorth: The Valuation Shield

Investor confidence was further by the structural between Cigna’s insurance arm and its health services division, Evernorth. Throughout the litigation, Evernorth, which houses Express Scripts, continued to post double-digit revenue growth, decoupling the *financial* performance of the PBM from the *political* toxicity of its business model. In 2024, Evernorth’s adjusted revenues surged 32 percent year-over-year, driven by specialty pharmacy services and biosimilar adoption. By the end of 2025, Evernorth contributed the majority of the group’s $274. 9 billion in total revenue. Investors recognized that the FTC’s complaint targeted specific rebate mechanics (specifically regarding insulin) rather than the entirety of Evernorth’s specialty drug supply chain. The market correctly bet that the high-margin specialty business would remain intact even if the insulin rebate arbitrage was dismantled.

“The market viewed the FTC action as a surgical strike on rebate arbitrage, not a nuclear strike on the PBM model. Cigna’s pivot to Evernorth’s service revenues provided a valuation floor that the litigation could not breach.”

The Settlement Rally: February 2026

The resolution of the administrative complaint on February 4, 2026, acted as a “clearing event” for the stock. The terms of the settlement, delinking rebates from list prices for insulin and repatriating Ascent Health Services from Switzerland to the U. S., were non-monetary in nature. The absence of a massive civil penalty or a forced breakup of the vertical integration stack was interpreted by the market as a victory for Cigna. Following the announcement, Cigna shares rallied approximately 3. 5 percent, reclaiming the $280 level. This positive price action confirmed that the market had priced in a “worst-case” scenario that never materialized. The settlement eliminated the tail risk of a protracted legal battle that could have exposed internal pricing documents to public scrutiny. also, the agreement to delink rebates aligns with broader industry trends toward “pass-through” models, which analysts had already identified as the future state of PBM contracting.

Comparative Performance

even with the regulatory headwinds, Cigna’s stock performance from the filing of the complaint to the settlement remained competitive with the broader healthcare sector. While it underperformed the S&P 500 during the height of the “PBM scrutiny” news pattern in mid-2025, the stock avoided the deep drawdowns seen in peers with higher exposure to Medicare Advantage rate cuts. The stability of Cigna’s stock during this period show a serious disconnect between regulatory rhetoric and financial reality. While the FTC described the insulin rebate practices as “unfair” and “anticompetitive,” investors viewed them as a legacy revenue stream that was already being phased out in favor of fees from specialty drug management. The settlement, therefore, was not a disruption of Cigna’s future value, a confirmation of it.

The Standard Offering: Mandating Net Cost Pricing for Plan Sponsors

Redefining the Default Contract Structure

The February 4, 2026, settlement between the Federal Trade Commission (FTC) and The Cigna Group’s Express Scripts introduced a structural remedy designed to the financial incentives driving insulin price inflation. Central to this agreement is the “Standard Offering,” a mandatory contract model that Express Scripts must present to all plan sponsors, including employers, unions, and health plans. Unlike previous opt-in transparency pilots, this provision compels the pharmacy benefit manager (PBM) to make net cost pricing the default baseline for its client negotiations, reversing the “opt-out” that previously favored unclear, rebate-driven arrangements.

Under the terms of the consent order, the Standard Offering requires that patient out-of-pocket costs, specifically deductibles and coinsurance, be calculated based on the drug’s net cost rather than its list price. Historically, while PBMs negotiated steep rebates that lowered the net cost of insulin for the plan sponsor, patients were frequently forced to pay cost-sharing amounts based on the artificially inflated Wholesale Acquisition Cost (WAC). The Standard Offering eliminates this by ensuring that the negotiated discounts are passed directly to the patient at the point of sale.

Mechanics of Net Cost Pricing

The shift to net cost pricing fundamentally alters the flow of capital between the manufacturer, the PBM, and the patient. In the traditional model, a $300 list price for a vial of insulin might carry a $200 rebate, resulting in a net cost of $100. yet, a patient with a 20% coinsurance or a high deductible would frequently pay based on the $300 figure. Under the Standard Offering, the patient’s financial obligation is tied strictly to the $100 net price. This method directly addresses the “rebate wall” allegation in the FTC’s September 2024 complaint, which argued that PBMs preferred high-list-price drugs to maximize the rebate dollars they could retain or use to offset premiums.

The settlement explicitly prohibits Express Scripts from basing its compensation on the list price of a drug within this Standard Offering. Instead, the PBM must adopt a “delinked” compensation model, earning revenue through flat administrative fees or clear service charges rather than a percentage of the drug’s sticker price. This decoupling is intended to remove the perverse incentive for the PBM to favor drugs with skyrocketing list prices solely to increase their own revenue share.

Eliminating Spread Pricing and Rebate Guarantees

Beyond patient-level costs, the Standard Offering mandates transparency for the plan sponsors themselves. The agreement requires Express Scripts to offer contracts that eliminate “spread pricing”, a practice where the PBM charges the plan sponsor a higher price for a drug than it reimburses the pharmacy, pocketing the difference. In the Standard Offering, the plan sponsor is billed the exact amount paid to the pharmacy plus a defined administrative fee.

also, the new model allows plan sponsors to transition away from “rebate guarantees.” In the past, PBMs frequently promised plan sponsors a guaranteed minimum rebate amount per script. While this offered predictability, it incentivized the PBM to curate formularies populated by high-list, high-rebate drugs to meet those guarantees, frequently at the expense of lower-cost generics or biosimilars. The Standard Offering provides a pathway for sponsors to reject these guarantees in favor of a full pass-through model, where 100% of the rebates and discounts negotiated with manufacturers are remitted to the plan.

Implementation Timeline and Adoption

The operational rollout of the Standard Offering follows a strict timeline mandated by the consent order. Express Scripts is required to implement specific behavioral remedies, including the cessation of preferential treatment for high-WAC drugs over identical low-WAC alternatives, by January 1, 2027. Cigna Group has committed to transitioning its own fully insured plans to this new model by the start of the 2027 plan year.

For external clients, the transition is gradual significant. Cigna executives projected that at least 50% of Evernorth’s clients would adopt the Standard Offering by the end of 2028. This phased adoption acknowledges the complexity of existing multi-year contracts establishes a clear trajectory toward the eradication of list-price-based contracting. The settlement remains in effect for ten years, ensuring long-term adherence to these structural changes.

Projected Impact on Insulin Affordability

The FTC estimates that the mandatory provisions of the Standard Offering reduce patient out-of-pocket costs for insulin and other highly rebated drugs by approximately $7 billion over the decade. This projection relies on the assumption that plan sponsors, when presented with the clear financial advantages of the net cost model for their members, overwhelmingly choose it over legacy arrangements.

also, the settlement expands the reach of the “Patient Assurance Program.” Express Scripts must provide full access to this program’s insulin benefits, which cap monthly costs, to all members whenever a plan sponsor adopts a formulary including a covered insulin product. Plan sponsors must explicitly opt out in writing if they wish to deny this benefit, a “nudge” tactic designed to maximize enrollment and patient savings.

Table 21. 1: Comparison of Legacy Contract vs. 2026 Standard Offering Mandate

Contract Feature	Legacy Model (Pre-2026)	Standard Offering (Post-Settlement)
Patient Cost Basis	List Price (WAC)	Net Cost (WAC minus Rebates)
PBM Compensation	% of List Price / Retained Rebates	Delinked Flat Administrative Fee
Rebate Flow	Partial Pass-Through / PBM Retains Share	100% Pass-Through to Plan Sponsor
Formulary Preference	High-List / High-Rebate Drugs	Lowest Net Cost (agnostic to List Price)
Spread Pricing	Common Revenue Source	Prohibited in Standard Offering

Integration of Direct-to-Consumer Platforms

A unique component of the Standard Offering is the required integration of “TrumpRx,” a federal direct-to-consumer drug pricing platform launched in early 2026. The settlement mandates that Express Scripts provide covered access to this platform as part of the Standard Offering. Crucially, purchases made through this channel must count toward the member’s deductible and out-of-pocket maximums. This provision forces the PBM to recognize and integrate lower-cost cash market alternatives into the insurance benefit, preventing the “double-paying” scenario where patients buying cheaper drugs outside their plan receive no credit toward their annual limits.

By institutionalizing the Standard Offering, the FTC settlement attempts to correct the market failure where intermediaries profited from complexity. The mandate shifts the default setting of the PBM-client relationship from opacity to transparency, theoretically aligning the incentives of the PBM with the financial health of the patient and the plan sponsor.

The Federal Trade Commission’s February 4, 2026, consent order imposes a rigid ten-year compliance framework upon The Cigna Group and its subsidiaries, Express Scripts and Ascent Health Services. This enforcement period, extending through 2036, subjects the pharmacy benefit manager (PBM) to federal oversight method designed to the “rebate wall” structures identified in the September 2024 administrative complaint. The settlement mandates the repatriation of offshore entities, the implementation of net-cost pricing models, and the systematic disclosure of financial data previously shielded by foreign jurisdictions and trade secret claims.

The Repatriation of Ascent Health Services

A central pillar of the enforcement order requires Cigna to reshore its group purchasing organization, Ascent Health Services, from Schaffhausen, Switzerland, to the United States. For the duration of the ten-year order, Ascent’s operations, handling billions in rebate negotiations, must fall under U. S. jurisdiction, stripping the entity of the regulatory opacity provided by Swiss domicile. The FTC’s stipulation demands that all purchasing activity, contracting, and financial records associated with Ascent be accessible to domestic auditors without the friction of international discovery processes. This closes the “Swiss Loophole” that allowed the PBM to shield rebate aggregation mechanics from U. S. regulators between 2019 and 2025.

Mandatory Net-Cost “Standard Offerings”

The consent decree compels Express Scripts to fundamentally alter its contract structures with plan sponsors. By January 1, 2027, the PBM must provide a “standard offering” that delinks manufacturer compensation from the list price of drugs.

Under this monitored model, Express Scripts is prohibited from preferring high-list-price (high-WAC) insulin products over therapeutically equivalent lower-cost versions on its standard formularies. The order enforces a “net cost” pass-through requirement, ensuring that the financial benefits of negotiated discounts reach the plan sponsors and patients rather than being retained as spread pricing or unclear fees. The FTC estimates this structural shift reduce patient out-of-pocket costs for insulin and related drugs by approximately $7 billion over the decade.

Compliance Reporting and Independent Auditing

To verify adherence to these prohibitions, the order establishes a rigorous reporting regime. Express Scripts must submit sworn compliance reports to the FTC, detailing its formulary construction methodologies and rebate flows.

The order prohibits Express Scripts from entering into agreements that exclude lower-cost drugs in favor of high-rebate alternatives, a practice the FTC defined as “rebate arbitrage.”

The enforcement method includes provisions for an independent monitor to audit Cigna’s adherence to the “lowest net cost” principle. This auditor have the authority to examine the PBM’s books to ensure that payments from drug manufacturers, whether labeled as administrative fees, data fees, or volume-based rebates, are fully disclosed and not used to artificially list prices.

Transparency in Broker Compensation

The settlement also the “steering” incentives within the PBM ecosystem. Express Scripts is required to disclose all payments made to benefits consultants and brokers who advise plan sponsors on PBM selection. Historically, these undisclosed payments created conflicts of interest, incentivizing consultants to recommend PBM contracts that prioritized high rebates over low net costs. The ten-year monitoring period requires these financial relationships to be transparent, allowing employers to see if their consultants are being paid to push higher-cost drug plans.

Penalties for Recidivism

Violations of the consent order carry significant consequences under Section 5(l) of the FTC Act. The Commission retains the authority to seek civil penalties for each violation of the order, which can accrue daily. also, the settlement does not shield Cigna from future antitrust action regarding conduct outside the specific scope of the insulin pricing allegations. While the February 2026 agreement resolves the administrative complaint regarding insulin, the structural changes, specifically the reshoring of Ascent and the transparency requirements, create a permanent evidentiary record that likely inform future regulatory scrutiny of the broader PBM industry.

FTC Consent Order: Key Enforcement Metrics (2026-2036)

Compliance Requirement	Deadline	Objective
Reshoring Ascent Health	Immediate / Transition by 2028	Bring GPO operations under U. S. jurisdiction; end Swiss regulatory arbitrage.
Net-Cost Standard Offering	January 1, 2027	Delink rebates from list prices; mandate pass-through of savings.
Low-WAC Preference	Immediate	Prohibit exclusion of lower-list-price drugs in favor of high-rebate alternatives.
Broker Payment Disclosure	Annual Reporting	Reveal kickbacks to consultants steering clients to high-cost plans.